The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Open accessAbstract
BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Evacetrapib, which raises HDL-C levels by 130% and lowers LDL-C by 37%, was studied in the ACCELERATE trial [63], which was terminated due to futility.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
In the citing paper
“Confounding by linkage disequilibrium can be assessed through colocalization 84”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Flagged first, then by citations
Research works printed but not linked: 1
- Krishna R, Clin Pharmacol Ther
Cited by
Sorted by citations
Items 101–200 of 1,001
Ray, K. K., Leiter, L. A., Müller‐Wieland, D., Cariou, B., Colhoun, H. M., Henry, R. R., Tinahones, F. J., Bujas‐Bobanovic, M., Domenger, C., Letierce, A., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13257 · Cited by 104
Determinants of cholesterol efflux capacity in humans
Talbot, C. P. J., Plat, J., Ritsch, A., & Mensink, R. P. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.12.001 · Cited by 99
Limitations of hazard ratios in clinical trials
Stensrud, M. J., Aalen, J. M., Aalen, O. O., & Valberg, M. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy770 · Cited by 99
Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis
Trinder, M., Genga, K. R., Kong, H. J., Blauw, L. L., Lo, C., Li, X., Cirstea, M. S., Wang, Y., Rensen, P. C. N., Russell, J. A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1157oc · Cited by 98
HDL and cardiovascular disease
Nicholls, S. J., & Nelson, A. J. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.017 · Cited by 104
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics
Vitali, C., Khetarpal, S. A., & Rader, D. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0940-0 · Cited by 96
Nurmohamed, N. S., Ditmarsch, M., & Kastelein, J. J. P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab350 · Cited by 99
Lipoprotein(a) and Cardiovascular Disease in Chinese Population
Li, J., Ma, C.-S., Zhao, D. H., Yan, X.-W., Li, J., Ma, C., Zhao, D. H., Yan, X.-W., Ye, P., Chen, H., et al. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.08.015 · Cited by 96
Goldstein, L. B., Toth, P. P., Dearborn, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., & Woo, D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 99
HDL in CKD—The Devil Is in the Detail
Kronenberg, F. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017070798 · Cited by 97
Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
Sniderman, A. D., Couture, P., Martin, S. S., DEGRAAF, J., Lawler, P. R., Cromwell, W. C., Wilkins, J. T., & Thanassoulis, G. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r082271 · Cited by 91
Georgakis, M. K., Malik, R., Anderson, C. D., Parhofer, K. G., Hopewell, J. C., & Dichgans, M. (2019) · Brain · doi:10.1093/brain/awz413 · Cited by 91
Atherosclerotic plaque stabilization and regression: a review of clinical evidence
Sarraju, A., & Nissen, S. E. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00979-8 · Cited by 96
Pol, T., Held, C., Westerbergh, J., Lindbäck, J., Alexander, J. H., Alings, M., Erol, Ç., Goto, S., Halvorsen, S., Huber, K., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007444 · Cited by 89
Principles and Applications of Rabbit Models for Atherosclerosis Research
Fan, J., Chen, Y., Yan, H., Niimi, M., Wang, Y., & Liang, J. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17018 · Cited by 87
Gragnano, F., & Calabrò, P. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.01.012 · Cited by 89
Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314050 · Cited by 88
Is a High HDL-Cholesterol Level Always Beneficial?
Franczyk, B., Rysz, J., Ławiński, J., Rysz-Górzyńska, M., & Gluba-Brzózka, A. (2021) · Biomedicines · doi:10.3390/biomedicines9091083 · Cited by 94
Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies
Kjeldsen, E. W., Thomassen, J. Q., Rasmussen, I. J., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab164 · Cited by 87
Existing and emerging strategies to lower Lipoprotein(a)
Schwartz, G. G., & Ballantyne, C. M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.020 · Cited by 86
HDL functionality in type 1 diabetes
Ganjali, S., Dallinga‐Thie, G. M., Simental‐Mendía, L. E., Banach, M., Pirro, M., & Sahebkar, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.018 · Cited by 84
Highlighting Residual Atherosclerotic Cardiovascular Disease Risk
Matsuura, Y., Kanter, J. E., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311999 · Cited by 88
Ballantyne, C. M., Ditmarsch, M., Kastelein, J. J. P., Nelson, A. J., Kling, D. F., Hsieh, A., Curcio, D. L., Maki, K. C., Davidson, M. H., & Nicholls, S. J. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.05.098 · Cited by 84
Guo, X., Gao, M., Wang, Y., Lin, X., Liu, Y., Cong, N., An, X., Wang, F., Qu, K., Yu, L., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.12.013 · Cited by 83
Millwood, I. Y., Bennett, D., Holmes, M. V., Boxall, R., Guo, Y., Bian, Z., Yang, L., Sansome, S., Chen, Y., Du, H., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4177 · Cited by 83
LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies
Revilla, G., Cedó, L., Tondo, M., Moral, A., Pérez, J. I., Corcoy, R., Lerma, E., Fusté, V., Reddy, S. T., Blanco‐Vaca, F., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.012 · Cited by 81
Brandts, J., & Ray, K. K. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.004 · Cited by 84
The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications
Wong, N. K. P., Nicholls, S. J., Tan, J. T. M., & Bursill, C. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061680 · Cited by 77
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 89
Pharmacological Intervention to Modulate HDL: What Do We Target?
Woudberg, N. J., Pedretti, S., Lecour, S., Schulz, R., Vuilleumier, N., James, R. W., & Frias, M. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00989 · Cited by 80
Parasrampuria, D. A., Benet, L. Z., & Sharma, A. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0204-y · Cited by 80
Novel Therapeutic Strategies to Reduce Reperfusion Injury After Acute Myocardial Infarction
Schäfer, A., König, T., Bauersachs, J. K., & Akin, M. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101398 · Cited by 80
Stahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Karjalainen, M. K., Holmes, M. V., Wang, Q., Anufrieva, O., Kähönen, M. A. P., Lehtimäki, T. J., Havulinna, A. S., Kristiansson, K., Salomaa, V. V., Perola, M., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.02.002 · Cited by 76
The potential of polygenic scores to improve cost and efficiency of clinical trials
Fahed, A. C., Philippakis, A., & Khera, A. V. (2022) · Nature Communications · doi:10.1038/s41467-022-30675-z · Cited by 72
Paraoxonase 1 and atherosclerosis
Durrington, P. N., Bashir, B., & Soran, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1065967 · Cited by 82
Diabetes Impairs Cellular Cholesterol Efflux From ABCA1 to Small HDL Particles
He, Y., Ronsein, G. E., Tang, C., Jarvik, G. P., Davidson, W. S., Kothari, V. M., Song, H. D., Segrest, J. P., Bornfeldt, K., & Heinecke, J. W. (2020) · Circulation Research · doi:10.1161/circresaha.120.317178 · Cited by 74
HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review
Kjeldsen, E. W., Nordestgaard, L. T., & Frikke‐Schmidt, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094547 · Cited by 76
Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments
Wolf, M., & Hunziker, P. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09961-y · Cited by 74
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 71
Effects of bariatric surgery on lipid-lipoprotein profile
Piché, M., Tardif, I., Auclair, A., & Poirier, P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154441 · Cited by 72
Nelson, A. J., Sniderman, A. D., Ditmarsch, M., Dicklin, M. R., Nicholls, S. J., Davidson, M. H., & Kastelein, J. J. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169417 · Cited by 72
Whole genome sequence analysis of blood lipid levels in >66,000 individuals
Selvaraj, M. S., Li, X., Li, Z., Pampana, A., Zhang, D. Y., Park, J., Aslibekyan, S. W., Bis, J. C., Brody, J. A., Cade, B. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33510-7 · Cited by 69
Lipid-lowering in diabetes: An update
Chait, A., Eckel, R. H., Vrablı́k, M., & Zambon, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117313 · Cited by 71
Cupido, A. J., Reeskamp, L. F., Hingorani, A. D., Finan, C., Asselbergs, F. W., Hovingh, G. K., & Schmidt, A. F. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2333 · Cited by 68
Itoh, H., Komuro, I., Takeuchi, M., Akasaka, T., Daida, H., Egashira, Y., Fujita, H., Higaki, J., Hirata, K., Ishibashi, S., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2224 · Cited by 71
Diabetogenic Action of Statins: Mechanisms
Carmena, R., & Betteridge, D. J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0780-z · Cited by 74
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
Kastelein, J. J. P., Hsieh, A., Dicklin, M. R., Ditmarsch, M., & Davidson, M. H. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01184-1 · Cited by 69
Rethinking good cholesterol: a clinicians' guide to understanding HDL
Xiang, A. S., & Kingwell, B. A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30003-8 · Cited by 70
Khan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871733 · Cited by 67
Georgakis, M. K., Malik, R., Li, X., Gill, D., Levin, M. G., Vy, H. M. T., Judy, R., Ritchie, M. D., Verma, S. S., Nadkarni, G. N., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052604 · Cited by 68
Unravelling HDL—Looking beyond the Cholesterol Surface to the Quality Within
Kajani, S., Curley, S., & McGillicuddy, F. C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071971 · Cited by 70
Hussain, S. M., Ebeling, P. R., Barker, A. L., Beilin, L. J., Tonkin, A. M., & McNeil, J. J. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2022.5124 · Cited by 66
Khan, A. A., Mundra, P. A., Straznicky, N. E., Nestel, P. J., Wong, G., Tan, R., Huynh, K., Ng, T. W., Mellett, N. A., Weir, J. M., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310212 · Cited by 66
Novel emerging therapies in atherosclerosis targeting lipid metabolism
Gupta, M., Blumenthal, C., Chatterjee, S., Bandyopadhyay, D., Jain, V., Lavie, C. J., Virani, S. S., Ray, K. K., Aronow, W. S., & Ghosh, R. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764937 · Cited by 67
HDL cholesterol and ASCVD risk stratification: A debate
Barter, P. J., & Genest, J. J. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.001 · Cited by 68
Kjeldsen, E. W., Thomassen, J. Q., & Frikke‐Schmidt, R. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159063 · Cited by 70
Very High High-Density Lipoprotein Cholesterol Levels and Cardiovascular Mortality
Liu, C., Dhindsa, D. S., Almuwaqqat, Z., Sun, Y. V., & Quyyumi, A. A. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.11.041 · Cited by 63
Molecular regulation of plasma lipid levels during systemic inflammation and sepsis
Trinder, M., Boyd, J. H., & Brunham, L. R. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000577 · Cited by 63
HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk
Allard‐Ratick, M., Kindya, B., Khambhati, J., Engels, M. C., Sandesara, P. B., Rosenson, R. S., & Sperling, L. S. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319848214 · Cited by 66
Genetics of extreme human longevity to guide drug discovery for healthy ageing
Zhang, Z. D., Milman, S., Lin, J.-R., Wierbowski, S. D., Yu, H., Barzilai, N., Gorbunova, V. A., Ladiges, W., Niedernhofer, L. J., Suh, Y., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0247-0 · Cited by 63
Nordestgaard, L. T., Christoffersen, M., Lauridsen, B. K., Afzal, S., Nordestgaard, B. G., Frikke‐Schmidt, R., & Tybjærg‐Hansen, A. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.3728 · Cited by 64
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
Riaz, H., Khan, S. U., Rahman, H., Shah, N. P., Kaluski, E., Lincoff, A. M., & Nissen, S. E. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318816495 · Cited by 61
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55-REVEAL Collaborative Group, Sammons, E. L., Hopewell, J. C., Chen, F., Stevens, W., Wallendszus, K., Valdés‐Márquez, E., Dayanandan, R., Knott, C., Murphy, K., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab863 · Cited by 62
Self-citationTherapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk
Masson, W. M., Lobo, M., Siniawski, D. A., Huerin, M. S., Molinero, G., Valéro, R., & Nogueira, J. P. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.005 · Cited by 60
Holmes, M. V., & Ala‐Korpela, M. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0157-6 · Cited by 61
Targeting cellular cholesterol for anticancer therapy
Gu, L., Saha, S. T., Thomas, J., & Kaur, M. (2019) · FEBS Journal · doi:10.1111/febs.15018 · Cited by 63
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19
Talasaz, A. H., Sadeghipour, P., Aghakouchakzadeh, M., Dreyfus, I., Kakavand, H., Ariannejad, H., Gupta, A., Madhavan, M. V., Tassell, B. W. V., Jiménez, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.021 · Cited by 59
Sarraju, A., Brennan, D. M., Hayden, K., Stronczek, A., Goldberg, A. C., Michos, E. D., McGuire, D. K., Mason, D., Tercek, G., Nicholls, S. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00721-4 · Cited by 64
Hunter, W. G., McGarrah, R. W., Kelly, J. P., Khouri, M. G., Craig, D. M., Haynes, C. S., Felker, G. M., Hernandez, A. F., Velazquez, E. J., Kraus, W. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.059 · Cited by 60
Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
Gareri, C., Polimeni, A., Giordano, S. A., Tammè, L., Curcio, A., & Indolfi, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133884 · Cited by 62
Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease
Zheng, W. C., Chan, W., Dart, A. M., & Shaw, J. A. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad074 · Cited by 62
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N. M., Skra, J., Valensi, P. E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0357-x · Cited by 59
Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids
Kris‐Etherton, P. M., Richter, C. K., Bowen, K. J., Skulas‐Ray, A. C., Jackson, K. H., Petersen, K. S., & Harris, W. S. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-3-171 · Cited by 63
Bruckert, É., Parhofer, K. G., González‐Juanatey, J. R., Nordestgaard, B. G., Arca, M., Giovas, P. P., & Ray, K. K. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01285-2 · Cited by 59
Mazidi, M., Mikhailidis, D. P., & Banach, M. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.095 · Cited by 58
Swerdlow, D. I., Rider, D. A., Yavari, A., Lindholm, M., Campion, G., & Nissen, S. E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab100 · Cited by 58
Galimberti, F., Casula, M., & Olmastroni, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106873 · Cited by 63
Hypercholesterolaemia – practical information for non-specialists
Soran, H., Adam, S., Mohamad, J. B., Ho, J. H., Schofield, J. D., Kwok, S., Siahmansur, T. J., Liu, Y., Syed, A. A., Dhage, S. S., et al. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.72238 · Cited by 59
Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management
Mytilinaiou, M. G., Kyrou, I., Khan, M., Grammatopoulos, D. K., & Randeva, H. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00707 · Cited by 61
Ala‐Korpela, M., Zhao, S., Järvelin, M., Mäkinen, V., & Ohukainen, P. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab156 · Cited by 57
Revealing the effect of CETP inhibition in cardiovascular disease
Holmes, M. V., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.156 · Cited by 56
Role of High‐Density Lipoproteins in Cholesterol Homeostasis and Glycemic Control
Manandhar, B., Cochran, B. J., & Rye, K. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013531 · Cited by 56
Present therapeutic role of cholesteryl ester transfer protein inhibitors
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.028 · Cited by 56
Masana, L., Ibarretxe, D., & Plana, N. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01326-w · Cited by 57
CETP (Cholesteryl Ester Transfer Protein) Concentration
Blauw, L. L., Li‐Gao, R., Noordam, R., de Mutsert, R., Trompet, S., Berbée, J. F. P., Wang, Y., van Klinken, J. B., Christen, T., van Heemst, D., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.117.002034 · Cited by 54
Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation
Tall, A. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.004 · Cited by 56
Ala‐Korpela, M. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz068 · Cited by 54
Furtado, J. D., Ruotolo, G., Nicholls, S. J., Dullea, R., Carvajal‐Gonzalez, S., & Sacks, F. M. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317181 · Cited by 53
High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus
He, Y., Kothari, V. M., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310222 · Cited by 56
Taheri, H., Filion, K. B., Windle, S. B., Reynier, P., & Eisenberg, M. J. (2020) · Cardiology · doi:10.1159/000505365 · Cited by 54
High Density Lipoproteins and Diabetes
Cochran, B. J., Ong, K. L., Manandhar, B., & Rye, K. (2021) · Cells · doi:10.3390/cells10040850 · Cited by 52
Kronenberg, F. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_504 · Cited by 54
LCAT- targeted therapies: Progress, failures and future
Yang, K., Wang, J., Xiang, H., Ding, P., Wu, T., & Ji, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112677 · Cited by 55
Antibiotic Resistance and Microbiota Response
Santacroce, L., Domenico, M. D., Montagnani, M., & Jirillo, E. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612829666221219093450 · Cited by 58
Common pitfalls in drug target Mendelian randomization and how to avoid them
Gill, D., Dib, M., Cronjé, H. T., Karhunen, V., Woolf, B. A. R., Gagnon, É., Daghlas, I., Nyberg, M., Drakeman, D. L., & Burgess, S. (2024) · BMC Medicine · doi:10.1186/s12916-024-03700-9 · Cited by 51
Saeed, A., & Ballantyne, C. M. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.007 · Cited by 51
The Role of High-Density Lipoprotein Cholesterol in 2022
Sirtori, C. R., Corsini, A., & Ruscica, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01012-y · Cited by 55
Metadata
- Authors
- The HPS3/TIMI55–REVEAL Collaborative Group
- Affiliations
- University of Oxford (GB)
- Corresponding author
- The HPS3/TIMI55–REVEAL Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-28
- Volume
- 377
- Issue
- 13
- Pages
- 1217-1227
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2762777606
- Cited by
- 1,047
- References
- 28
- Citations by year
- 2026: 72 · 2025: 78 · 2024: 99 · 2023: 92 · 2022: 93 · 2021: 118 · 2020: 107 · 2019: 134 · 2018: 195 · 2017: 54
- FWCI
- 137.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10139, NF-SI-0508-10299, RC-PG-0407-10054)
- British Heart Foundation (FS/14/55/30806)
- Versus Arthritis (20639, 18475)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibition, atherosclerosis, coronary events, myocardial infarction, coronary revascularization, coronary death, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, atorvastatin, statin therapy, cardiovascular risk reduction, serious adverse events, cancer risk, drug safety, subgroup analysis
- MeSH terms
- Aged, Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Oxazolidinones, Atherosclerosis, Kaplan-Meier Estimate, Cholesterol Ester Transfer Proteins, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
